Inventor · disambiguated record
Kenneth W. Walker
Also filed as: WALKER KENNETH · WALKER KENNETH W · WALKER KENNETH WILLIAM
36 granted patents·16 pending applications·380 citations·filing 2002–2025
97Inventor score
Top patents by PatentIndex Score
52 records- 0196US8993727B2Carrier immunoglobulins and uses thereofWALKER KENNETH W·Filed 2011·Granted Mar 31, 2015·38 cites·16 claims
- 0296US8008453B2Modified Fc moleculesAMGEN INC·Filed 2006·Granted Aug 30, 2011·55 cites·19 claims
- 0395US7833979B2Toxin peptide therapeutic agentsAMGEN INC·Filed 2006·Granted Nov 16, 2010·45 cites·31 claims
- 0494US8907071B2Toxin peptide therapeutic agentsSULLIVAN JOHN K·Filed 2010·Granted Dec 9, 2014·61 cites·24 claims
- 0593US8420779B2Compositions and methods for producing bioactive fusion proteinsWALKER KENNETH W·Filed 2008·Granted Apr 16, 2013·18 cites·18 claims
- 0693US8143380B2Therapeutic peptidesWALKER KENNETH W·Filed 2005·Granted Mar 27, 2012·14 cites·11 claims
- 0792US9862752B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2014·Granted Jan 9, 2018·16 cites·27 claims
- 0892US9714276B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2013·Granted Jul 25, 2017·17 cites·18 claims
- 0991US11891435B2Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereofAMGEN INC·Filed 2021·Granted Feb 6, 2024·1 cites·24 claims
- 1091US11161889B2Growth differentiation factor 15 fusion proteinsAMGEN INC·Filed 2021·Granted Nov 2, 2021·2 cites·11 claims
- 1191US10738110B2PAC1 antibodies and uses thereofAMGEN INC·Filed 2019·Granted Aug 11, 2020·3 cites·17 claims
- 1291US10336798B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2017·Granted Jul 2, 2019·9 cites·21 claims
- 1390US10894814B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2017·Granted Jan 19, 2021·4 cites·25 claims
- 1489US7834164B2DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expressionAMGEN INC·Filed 2007·Granted Nov 16, 2010·9 cites·8 claims
- 1589US7820623B2Conjugated toxin peptide therapeutic agentsAMGEN INC·Filed 2007·Granted Oct 26, 2010·10 cites·23 claims
- 1687US9562108B2Carrier immunoglobulinsAMGEN INC·Filed 2014·Granted Feb 7, 2017·8 cites·24 claims
- 1785US11248043B2Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereofAMGEN INC·Filed 2020·Granted Feb 15, 2022·1 cites·33 claims
- 1885US8541201B2Thrombopoietic compoundsMIN HOSUNG·Filed 2011·Granted Sep 24, 2013·9 cites·4 claims
- 1985US8043829B2DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expressionAMGEN INC·Filed 2007·Granted Oct 25, 2011·6 cites·19 claims
- 2084US11739131B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2019·Granted Aug 29, 2023·1 cites·6 claims
- 2184US8633153B2Transthyretin variantsWALKER KENNETH WILLIAM·Filed 2009·Granted Jan 21, 2014·9 cites·15 claims
- 2284US8168592B2CGRP peptide antagonists and conjugatesGEGG JR COLIN V·Filed 2006·Granted May 1, 2012·23 cites·11 claims
- 2384US2024368236A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2024·Application pending·0 cites
- 2482US11104745B2Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereofAMGEN INC·Filed 2016·Granted Aug 31, 2021·5 cites·20 claims
- 2582US8734796B2Carrier immunoglobulinsWALKER KENNETH W·Filed 2010·Granted May 27, 2014·5 cites·22 claims
- 2682US7910102B2Methods of using conjugated toxin peptide therapeutic agentsAMGEN INC·Filed 2007·Granted Mar 22, 2011·4 cites·12 claims
- 2781US2024150448A1Pac1 antibodies and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2881US2024327481A1Growth differentiation factor 15 fusion proteinsAMGEN INC·Filed 2024·Application pending·0 cites
- 2980US12269898B2Transthyretin immunoglobulin fusionsAMGEN INC·Filed 2018·Granted Apr 8, 2025·1 cites·33 claims
- 3080US9279013B2FGF-21 mutants comprising polyethylene glycol and uses thereofWALKER KENNETH W·Filed 2009·Granted Mar 8, 2016·3 cites·53 claims
- 3178US2025319196A1Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteinsAMGEN INC·Filed 2025·Application pending·0 cites
- 3278US2024261421A1Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteinsAMGEN INC·Filed 2024·Application pending·0 cites
- 3377US7981425B2Thrombopoietic compoundsAMGEN INC·Filed 2007·Granted Jul 19, 2011·2 cites·1 claims
- 3473US11266744B2Modified Fc moleculesAMGEN INC·Filed 2018·Granted Mar 8, 2022·0 cites·24 claims
- 3573US9562107B2Carrier immunoglobulinsAMGEN INC·Filed 2014·Granted Feb 7, 2017·1 cites·24 claims
- 3672US12054527B2Growth differentiation factor 15 fusion proteinsAMGEN INC·Filed 2019·Granted Aug 6, 2024·0 cites·19 claims
- 3772US2022017584A1Growth differentiation factor 15 fusion proteinsAMGEN INC·Filed 2021·Application pending·0 cites
- 3870US2021079051A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2020·Application pending·0 cites
- 3965US12465652B2Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteinsAMGEN INC·Filed 2018·Granted Nov 11, 2025·0 cites·20 claims
- 4060US10189912B2Carrier immunoglobulinsAMGEN INC·Filed 2017·Granted Jan 29, 2019·0 cites·24 claims
- 4159US2013217625A1Compositions and methods for producing bioactive fusion proteinsAMGEN INC·Filed 2013·Application pending·0 cites
- 4259US2013209466A1Compositions and methods for producing bioactive fusion proteinsAMGEN INC·Filed 2013·Application pending·0 cites
- 4359US2003195154A1Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteinsFiled 2003·Application pending·0 cites
- 4459US2014234945A1Transthyretin variantsAMGEN INC·Filed 2014·Application pending·0 cites
- 4556US10188740B2Modified Fc moleculesAMGEN INC·Filed 2015·Granted Jan 29, 2019·0 cites·33 claims
- 4656US2003191056A1Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteinsFiled 2002·Application pending·0 cites
- 4754US2022324924A1Multispecific transthyretin immunoglobulin fusionsAMGEN INC·Filed 2020·Application pending·0 cites
- 4850US9803019B2Carrier immunoglobulins and uses thereofAMGEN INC·Filed 2015·Granted Oct 31, 2017·0 cites·26 claims
- 4949US9114175B2Modified Fc moleculesGEGG COLIN V·Filed 2011·Granted Aug 25, 2015·0 cites·21 claims
- 5049US2022363770A1Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteinsAMGEN INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →